Clal Biotechnology Industries (CBI)
Investor Israel Est. 1993
Team
3
Confidence
55/100
News
12
articles
About
Clal Biotechnology Industries is a life sciences investment company. CBI is focused on identifying and supporting promising innovative ventures, developing proprietary solutions, addressing unmet medical needs with multibillion-dollar market potential. Clal Biotechnology Industries provides its companies access to the global biotechnology industry. Clal Biotechnology Industries invests in companies ranging from seed to maturity, both public and private. It applies diverse models of strategic cooperation, providing significant investments together with hands-on leadership and guidance. CBIs investments range from biotech and pharma to diagnostics and medical devices. Its team maximizes the value of existing investments, contributes to the development of investee companies and finds new investments and business opportunities with great potential returns in Israel and the United States. CBI's stockholders are Clal Industries, which holds a portfolio of investments from heavy industry to biotechnology, hi-tech and energy companies. Clal Industries is fully owned by Access Industries, a privately-held industrial group with long-term holdings in the sectors of natural resources and chemical, media and telecommunications, venture capital and real estate
Classification
Tags
medical-devicesdiagnosticsbiotechnologypharmaceuticalsmedical-technologiesdigital-healthcare
News (12)
Jul 14, 2021 · www.sponser.co.il
growth-positive
כלל ביו: אליסיו פרסמה תשקיף להנפקה בארה"ב
Public Trading
Jun 16, 2021 · en.globes.co.il
growth-positive
Clal Biotech and partners file to raise $100m Nasdaq SPAC
AcquisitionPublic TradingManagement Changes
Mar 18, 2021 · en.globes.co.il
growth-positive
Clal Biotech to form $100m SPAC
Public TradingPartners
Aug 19, 2020 · en.globes.co.il
growth-positive
Clal Biotech jumps as portfolio co joins Covid-19 vaccine race
InvestmentPublic Trading
Apr 9, 2017 · www.globes.co.il
growth-positive
Yelin Lapidot to invest NIS 20m in Clal Biotech
Investment
Mar 8, 2017 · www.globes.co.il
growth-positive
Clal Biotech co Luk buys Ataxion Therapeutics
AcquisitionInvestment
Jan 23, 2017 · www.globes.co.il
growth-positive
Clal Biotech appoints Julian Adams president
Management Changes
Sep 3, 2015 · www.globes.co.il
growth-negative
Andromeda trial failure spells likely end of company
Investment
Mar 18, 2015 · www.globes.co.il
growth-positive
Clal Biotech unit signs Novartis deal
Partners
Oct 27, 2014 · jewishbusinessnews.com
growth-positive
Clal Biotech Sells Pidilizumab Cancer Treatment Rights to Medivation
Partners
Mar 10, 2013 · www.globes.co.il
growth-positive
Clal Biotech to pay $7.5m for Blavatnik cos - in 12 years
Acquisition
Mar 1, 2010 · www.globes.co.il
growth-positive
Clal Biotech buys Biomedical Investments
Acquisition
Locations
Azrieli Center, Derech Menachem Begin, Tel Aviv, Israel
1 Kendall Street, Cambridge, MA, USA
Links
Website
LinkedIn
Admin
Last Update
May 26, 2025
Verified by
Jenny Sotnik-Talisman
Missing
product stage, sector, number of employees, business model, tag line, video or image, funding rounds, markets, not claimed
Team (3)
Assaf Segal
CEO
Arnon Aharon
Medical Director
Camila Namer
HRBP
Internal
Created
2015-08-06T00:00:00.000Z
Last editor
Ortal Wein (ortalw@sncentral.org)
Status
Public on TASE on May, 2007;
Recent activity
Ortal Wein · Manual · 2022-11-16 11:45:08.000000
Ortal Wein · Manual · 2022-11-16 11:47:55.000000
Ortal Wein · Manual · 2022-11-16 11:41:49.000000
Ortal Wein · Manual · 2022-11-16 11:50:29.000000
Ortal Wein · Manual · 2022-11-16 11:38:45.000000
Matan Eblagon · Manual · 2025-05-26 11:05:09.000000
Ortal Wein · Manual · 2022-11-16 11:54:01.000000
Ortal Wein · Manual · 2022-11-16 11:45:16.000000
Ortal Wein · Manual · 2022-11-16 11:45:08.000000
Matan Eblagon · Manual · 2025-05-26 11:05:08.000000